Phase II trial of talazoparib in HER- breast cancer with somatic BRCA1/2 mutations

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, discusses a Phase II trial (NCT03990896) evaluating talazoparib, a PARP inhibitor, in patients with HER2- metastatic breast cancer and somatic BRCA1/2 mutations, identified via cell-free DNA or tumor genotyping. Progression-free survival will be the primary endpoint and the study also examines genomic changes and biomarker correlations. The findings could broaden PARP inhibitor applicability beyond germline BRCA1/2 mutations, offering new therapeutic options for this patient subgroup. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.